Compare RXT & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RXT | MCRB |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.5M | 139.7M |
| IPO Year | 2020 | 2015 |
| Metric | RXT | MCRB |
|---|---|---|
| Price | $1.23 | $8.84 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $1.71 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 7.4M | 39.3K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.13 | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | ★ $2,685,700,000.00 | $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.35 | N/A |
| P/E Ratio | ★ N/A | $13.45 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $0.36 |
| 52 Week High | $2.74 | $29.98 |
| Indicator | RXT | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 47.56 | 46.20 |
| Support Level | $1.16 | $7.98 |
| Resistance Level | $1.32 | $9.53 |
| Average True Range (ATR) | 0.14 | 0.59 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 68.27 | 40.59 |
Rackspace Technology Inc is an end-to-end, hybrid, multi-cloud technology services company. It designs, builds, and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services, Data, Colocation, Cloud, Managed Hosting, Professional Services, and Security and Compliance. It has two reportable segments: Private Cloud and Public Cloud. Maximum revenue is generated from the Public Cloud segment, which offers cloud solutions through managed services, elastic engineering, and professional services offerings for customer environments hosted on the AWS, Microsoft Azure, and Google Cloud public cloud platforms. Geographically, the company derives its key revenue from the U.S.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.